Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Reconstitution of the human 5-HT(1D) receptor-G-protein coupling: evidence for constitutive activity and multiple receptor conformations.

Brys R, Josson K, Castelli MP, Jurzak M, Lijnen P, Gommeren W, Leysen JE.

Mol Pharmacol. 2000 Jun;57(6):1132-41.

PMID:
10825383
2.

Mapping of serotonin 5-HT(4) receptor mRNA and ligand binding sites in the post-mortem human brain.

Bonaventure P, Hall H, Gommeren W, Cras P, Langlois X, Jurzak M, Leysen JE.

Synapse. 2000 Apr;36(1):35-46.

PMID:
10700024
3.

Structure of the human serotonin 5-HT4 receptor gene and cloning of a novel 5-HT4 splice variant.

Bender E, Pindon A, van Oers I, Zhang YB, Gommeren W, Verhasselt P, Jurzak M, Leysen J, Luyten W.

J Neurochem. 2000 Feb;74(2):478-89.

4.

Efficient expression of neurotransmitter receptors in mammalian cells: use of inducible expression systems.

Vanhoenacker P, Van den Bogerd I, Gommeren W, Luyten WH, Leysen JE, Haegeman G.

Ann N Y Acad Sci. 1998 Dec 15;861:236-7. No abstract available.

PMID:
9928263
5.

Cloning and expression of a human serotonin 5-HT4 receptor cDNA.

Van den Wyngaert I, Gommeren W, Verhasselt P, Jurzak M, Leysen J, Luyten W, Bender E.

J Neurochem. 1997 Nov;69(5):1810-9.

6.

Stable, high-level expression of human serotonin receptors in L929 cells using an inducible expression system.

Vanhoenacker P, Gommeren W, Luyten WH, Leysen JE, Haegeman G.

Receptors Channels. 1997;5(3-4):125-37.

PMID:
9606717
7.
8.

Seasonal variation in platelet [3H]paroxetine binding in healthy volunteers. Relationship to climatic variables.

D'Hondt P, Maes M, Leysen JE, Gommeren W, Heylen L, DeMeyer F, Scharpe S, Peeters D, Desnyder R.

Neuropsychopharmacology. 1996 Aug;15(2):187-98.

9.

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.

Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE.

Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73.

PMID:
8935801
10.

Evaluation of radioiodo-4-amino-N-[1-[3-(4-fluorophenoxy)-propyl]-4- methyl-4-piperidinyl]-5-iodo-2-methoxybenzamide as a potential 5HT2 receptor tracer for SPE(C)T.

Terriere D, Janssen PM, Gommeren W, Gysemans M, Mertens JJ, Leysen JE.

Nucl Med Biol. 1995 Nov;22(8):1005-5. No abstract available.

PMID:
8998459
11.

Binding of [3H]paroxetine to platelets of depressed patients: seasonal differences and effects of diagnostic classification.

D'Hondt P, Maes M, Leysen JE, Gommeren W, Scharpé S, Cosyns P.

J Affect Disord. 1994 Sep;32(1):27-35.

PMID:
7798464
12.

Genomic cloning, heterologous expression and pharmacological characterization of a human histamine H1 receptor.

De Backer MD, Gommeren W, Moereels H, Nobels G, Van Gompel P, Leysen JE, Luyten WH.

Biochem Biophys Res Commun. 1993 Dec 30;197(3):1601-8.

PMID:
8280179
14.

Autoradiographic evidence for the occlusion of rat brain dopamine D3 receptors in vivo.

Schotte A, Janssen PF, Gommeren W, Luyten WH, Leysen JE.

Eur J Pharmacol. 1992 Aug 6;218(2-3):373-5.

PMID:
1425949
15.

In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone.

Leysen JE, Janssen PM, Gommeren W, Wynants J, Pauwels PJ, Janssen PA.

Mol Pharmacol. 1992 Mar;41(3):494-508.

PMID:
1372084
16.

[Non-sedative antihistaminics and binding to central and peripheral H1 histamine receptors].

Leysen JE, Gommeren W, Janssen PF, Sanz G, Gillardin JM, Schotte A, Janssen PA.

Allerg Immunol (Paris). 1991 Feb;23(2):51-7. French.

PMID:
1677249
17.

Identification of non-serotonergic [3H]ketanserin binding sites on human platelets and their role in serotonin release.

Leysen JE, Gommeren W, Janssen PA.

Eur J Pharmacol. 1991 Jan 25;206(1):39-45.

PMID:
2065715
18.

The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various beta-adrenergic blockers.

Pauwels PJ, Gommeren W, Van Lommen G, Janssen PA, Leysen JE.

Mol Pharmacol. 1988 Dec;34(6):843-51.

PMID:
2462161
19.

Biochemical profile of risperidone, a new antipsychotic.

Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PA.

J Pharmacol Exp Ther. 1988 Nov;247(2):661-70.

PMID:
2460616
20.

Comparison of the in-vitro receptor selectivity of substituted benzamide drugs for brain neurotransmitter receptors.

Chivers JK, Gommeren W, Leysen JE, Jenner P, Marsden CD.

J Pharm Pharmacol. 1988 Jun;40(6):415-21.

PMID:
2901473
23.

Receptor interactions of dopamine and serotonin antagonists: binding in vitro and in vivo and receptor regulation.

Leysen JE, Gommeren W, Janssen PF, Van Gompel P, Janssen PA.

Psychopharmacol Ser. 1988;5:12-26. Review.

PMID:
3045796
25.

Non-serotonergic [3H]ketanserin binding sites in striatal membranes are associated with a dopac release system on dopaminergic nerve endings.

Leysen JE, Eens A, Gommeren W, Van Gompel P, Wynants J, Janssen PA.

Eur J Pharmacol. 1987 Feb 24;134(3):373-5. No abstract available.

PMID:
3569421
26.

Differential regulation of dopamine-D2 and serotonin-S2 receptors by chronic treatment with the serotonin-S2 antagonists, ritanserin, and setoperone.

Leysen JE, van Gompel P, Gommeren W, Laduron PM.

Psychopharmacol Ser. 1987;3:214-24. No abstract available.

PMID:
2950521
27.

Down regulation of serotonin-S2 receptor sites in rat brain by chronic treatment with the serotonin-S2 antagonists: ritanserin and setoperone.

Leysen JE, Van Gompel P, Gommeren W, Woestenborghs R, Janssen PA.

Psychopharmacology (Berl). 1986;88(4):434-44.

PMID:
3010361
28.

Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.

Leysen JE, Gommeren W, Van Gompel P, Wynants J, Janssen PF, Laduron PM.

Mol Pharmacol. 1985 Jun;27(6):600-11.

PMID:
2860558
30.

3H-Ketanserin labels serotonin S2-receptor binding sites on cat blood platelets.

Leysen JE, Gommeren W, De Clerck F.

Arch Int Pharmacodyn Ther. 1983 Jun;263(2):322-4. No abstract available.

PMID:
6882104
31.

Interaction of peptides and morphine-like narcotic analgesics with specifically labelled mu- and delta-opiate receptor binding sites.

Hermans B, Gommeren W, De Potter WP, Leysen JE.

Arch Int Pharmacodyn Ther. 1983 Jun;263(2):317-9. No abstract available.

PMID:
6136260
32.

Demonstration of S2-receptor binding sites on cat blood platelets using [3H]ketanserin.

Leysen JE, Gommeren W, De Clerck F.

Eur J Pharmacol. 1983 Mar 18;88(1):125-30.

PMID:
6852103
33.
34.

Demonstration of a complex subunit composition of a unitary dopamine receptor: effects of lesions and proteolytic enzymes on stereospecific binding.

Leysen JE, Gommeren W, Van Gompel P.

Adv Biochem Psychopharmacol. 1983;36:147-62. No abstract available.

PMID:
6858752
35.

In vitro binding properties of 3H-sufentanil, a superior ligand for the mu-opiate receptor.

Leysen JE, Gommeren W.

Arch Int Pharmacodyn Ther. 1982 Dec;260(2):287-9. No abstract available.

PMID:
6131653
36.

Solubilized opiate receptors labelled with 3H-lofentanil.

Ilien B, Gommeren W, Leysen JE, Laduron PM.

Arch Int Pharmacodyn Ther. 1982 Aug;258(2):313-6. No abstract available.

PMID:
6291473
37.

Binding properties of 3H-lofentanil at the opiate receptor.

Gommeren W, Leysen JE.

Arch Int Pharmacodyn Ther. 1982 Jul;258(1):171-3. No abstract available.

PMID:
6291471
38.

Regional distribution of serotonin-2 receptor binding sites in the brain and effects of neuronal lesions.

Leysen JE, Geerts R, Gommeren W, Verwimp M, Van Gompel P.

Arch Int Pharmacodyn Ther. 1982 Apr;256(2):301-5. No abstract available.

PMID:
7103617
39.

In vitro and in vivo binding characteristics of a new long-acting histamine H1 antagonist, astemizole.

Laduron PM, Janssen PF, Gommeren W, Leysen JE.

Mol Pharmacol. 1982 Mar;21(2):294-300.

PMID:
6124876
40.

Chronic neuroleptic treatment specifically alters the number of dopamine receptors in rat brain.

Theodorou A, Gommeren W, Clow A, Leysen J, Jenner P, Marsden CD.

Life Sci. 1981 Apr 6;28(14):1621-7. No abstract available.

PMID:
7242249
41.
43.

Evidence for, and localization of, a unitary dopamine receptor composed of cooperatively linked subunit binding sites in rat striatum.

Leysen JE, Gommeren W, Laduron PM.

Arch Int Pharmacodyn Ther. 1979 Dec;242(2):312-4. No abstract available.

PMID:
543764
44.

Distinction between dopaminergic and serotonergic components of neuroleptic binding sites in limbic brain areas.

Leysen JE, Gommeren W, Laduron PM.

Biochem Pharmacol. 1979;28(3):447-8. No abstract available.

PMID:
34403
45.

Endogenous ligands for CNS drug receptors?

Leysen JE, Gommeren W, Laduron PM.

Arch Int Pharmacodyn Ther. 1978 Dec;236(2):310-4. No abstract available.

PMID:
218510
46.

Kinetic investigation of [3H] spiperone-binding sites in rat frontal cortex [proceedings].

Leysen JE, Gommeren W, Laduron P.

Arch Int Physiol Biochim. 1978 Oct;86(4):874-6. No abstract available.

PMID:
84588
47.

Different kinetic properties of neuroleptic receptor binding in the rat striatum and frontal cortex.

Leysen JE, Gommeren W.

Life Sci. 1978 Aug 7;23(5):447-52. No abstract available.

PMID:
29187
48.

Spiperone: a ligand of choice for neuroleptic receptors. 1. Kinetics and characteristics of in vitro binding.

Leysen JE, Gommeren W, Laduron PM.

Biochem Pharmacol. 1978 Feb 1;27(3):307-16. No abstract available.

PMID:
23126
49.

Discrimination of narcotic drugs on 3H-fentanyl receptor binding.

Leysen J, Gommeren W, Laduron P.

Arch Int Pharmacodyn Ther. 1976 Apr;220(2):335-8.

PMID:
952589
50.

Supplemental Content

Loading ...
Support Center